Drug–drug interactions and risk of central nervous system depression in preterm infants: Clinical outcomes from a prospective study
British Journal of Clinical Pharmacology · 15.11.2026
DOI: 10.1002/bcp.70924 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 15.11.2026. Verfasst von Daniel Paiva Marques und 6 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Pharmaceutical Science, Health Science Center, Federal University of Rio Grande do Norte, Natal, Brazil. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).
Themen: Neonatologie, Depression
Abstract (Originalsprache)
Aim
Neonates admitted to neonatal intensive care units (NICUs) are frequently exposed to central nervous system (CNS) depressant medications, increasing the risk of potential drug–drug interactions (DDIs). However, evidence on the clinical outcomes associated with these interactions remains limited. This study evaluated the association between DDIs with the potential for CNS depression and clinical outcomes in neonates admitted to a NICU.
Methods
This prospective observational cohort study included 600 neonates admitted to a NICU in Brazil. Pharmacotherapy was monitored daily, and DDIs with the potential for CNS depression were identified using the UpToDate® database. Clinical outcomes associated with specific drug combinations were analysed.
Results
A total of 89 neonates (14.8%) were exposed to at least one DDI with the potential for CNS depression. These interactions were associated with a higher occurrence of hypoactivity, reduced peripheral oxygen saturation and mortality. The fentanyl/phenobarbital combination showed the most consistent risk profile, being associated with all evaluated outcomes. Interactions involving magnesium sulphate were associated with reduced oxygen saturation, while fentanyl/fluconazole was associated with increased mortality.
Conclusion
DDIs with the potential for CNS depression were associated with clinically relevant adverse outcomes in neonates. The findings highlight fentanyl/phenobarbital as the combination of greatest clinical concern and suggest that oxygen saturation may be a useful marker for monitoring CNS‐related DDIs in neonatal intensive care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Postgraduate Program in Pharmaceutical Science, Health Science Center, Federal University of Rio Grande do Norte, Natal, Brazil.
- Postgraduate Program in Pharmaceutical Services and Policies, Health Science Center, Federal University of Rio Grande do Norte, Natal, Brazil.
- School Maternity Januário Cicco (MEJC/EBSERH), Health Science Center, Federal University of Rio Grande do Norte, Natal, Brazil.
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Zitieren
APA
Marques, D. P., da Silva, A. K. F., de Oliveira Pedrosa, N. B., do Nascimento Granjeiro Barreto, A. C., de Medeiros, I. U., de Alencar Morais Lima, W., & Martins, R. R. (2026). Drug–drug interactions and risk of central nervous system depression in preterm infants: Clinical outcomes from a prospective study. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70924
Vancouver
Marques DP, da Silva AKF, de Oliveira Pedrosa NB, do Nascimento Granjeiro Barreto AC, de Medeiros IU, de Alencar Morais Lima W, et al. Drug–drug interactions and risk of central nervous system depression in preterm infants: Clinical outcomes from a prospective study. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70924
BibTeX
@article{Marques2026,
author = {Marques, Daniel Paiva and da Silva, Andreza Kelly Fernandes and de Oliveira Pedrosa, Nathália Beatriz and do Nascimento Granjeiro Barreto, Anna Christina and de Medeiros, Iris Ucella and de Alencar Morais Lima, Waldenice and Martins, Rand Randall},
title = {Drug–drug interactions and risk of central nervous system depression in preterm infants: Clinical outcomes from a prospective study},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70924}
}
EUVIMED